|
|
Outcomes
and prognostic factors in recurrent glioma patients enrolled onto phase II
clinical trials
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA,
Yung WK
Departments of Neuro-Oncology and Biomathematics, The University
of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Purpose. To determine aggregate outcomes and prognostic covariates in
patients with recurrent glioma enrolled onto phase II chemotherapy trials.
Patients
and Methods. Patients from eight consecutive phase II trials included 225
with recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic
astrocytoma (AA).
Their median age was 45 years (range, 15 to 82 years) and their median Karnofsky
performance score was 80 (range, 60 to 100).
Prognostic covariates were analyzed with respect to tumor response,
progression-free survival (PFS), and overall survival (OS) by multivariate
logistic and Cox proportional hazards regression analyses.
Results.
Overall, 34 (9%) had complete or partial response, whereas 80 (21%) were alive
and progression-free at 6 months (APF6).
The median PFS was 10 weeks and median OS was 30 weeks.
Histology was a robust prognostic factor across all outcomes.
GBM patients had significantly poorer outcomes than AA patients.
The APF6 proportion was 15% for GBM and 31% for AA, whereas the median PFS was 9
weeks for GBM and 13 weeks for AA.
Results were also significantly poorer for patients with more than two prior
surgeries or chemotherapy regimens.
Conclusion.
Histology is a dominant factor in determining outcome in patients with recurrent
glioma enrolled onto phase II trials.
Future trials should be designed with separate histology strata.
PMID: 10561324 [PubMed - indexed for MEDLINE]
|
